Annual report
4544.TEDINET S100OATL
Period2021-04-01 → 2022-03-31
Filed2022-06-22
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 154
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥272.9bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales |
| Revenue | ¥223.0bn | 2020-04-01 → 2021-03-31 | Cons. | Net sales |
| Revenue | ¥188.7bn | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥181.4bn | 2018-04-01 → 2019-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥195.4bn | 2017-04-01 → 2018-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥50.5bn | 2021-04-01 → 2022-03-31 | Cons. | Operating income |
| Operating income | ¥25.4bn | 2020-04-01 → 2021-03-31 | Cons. | Operating income |
| Ordinary income | ¥47.4bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥25.5bn | 2020-04-01 → 2021-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥6.5bn | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥11.5bn | 2018-04-01 → 2019-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥16.6bn | 2017-04-01 → 2018-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥41.3bn | 2021-04-01 → 2022-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥20.8bn | 2020-04-01 → 2021-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥29.6bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥17.5bn | 2020-04-01 → 2021-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥516m | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥6.4bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥257m | 2017-04-01 → 2018-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥29.6bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss |
| Net income | ¥17.4bn | 2020-04-01 → 2021-03-31 | Cons. | Profit loss |
| Total assets | ¥286.6bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥252.8bn | at 2021-03-31 | Cons. | Assets |
| Total assets | ¥219.4bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥201.2bn | at 2019-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥176.1bn | at 2018-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥146.4bn | at 2022-03-31 | Cons. | Liabilities |
| Total liabilities | ¥137.5bn | at 2021-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥140.2bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥115.3bn | at 2021-03-31 | Cons. | Net assets |
| Net assets / equity | ¥103.2bn | at 2020-03-31d | Cons. | Net assets |
| Net assets / equity | ¥113.0bn | at 2019-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥113.2bn | at 2018-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥46.5bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥43.0bn | at 2021-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥46.5bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥43.0bn | at 2021-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥36.2bn | at 2020-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥33.7bn | at 2019-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥20.4bn | at 2018-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥55.2bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥35.6bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥15.2bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥16.2bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥15.8bn | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥30.9bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥28.3bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥21.8bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥34.9bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥21.6bn | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥21.7bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.6bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥8.2bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥32.0bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥9.6bn | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥519.55 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥306.38 | 2020-04-01 → 2021-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-9.06 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥111.94 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥4.51 | 2017-04-01 → 2018-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥519.42 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥306.32 | 2020-04-01 → 2021-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥111.91 | 2018-04-01 → 2019-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥4.51 | 2017-04-01 → 2018-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥2,463.33 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,020.01 | at 2021-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,809.18 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,980.27 | at 2019-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,979.78 | at 2018-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 48.9% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 45.6% | at 2021-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 47.0% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 56.0% | at 2019-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 64.2% | at 2018-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 23.2% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 16.0% | 2020-04-01 → 2021-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.7% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 0.2% | 2017-04-01 → 2018-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 5,444 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 5,897 | at 2021-03-31 | Cons. | Number of employees |
| Employees | 5,968 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 5,957 | at 2019-03-31d | Cons. | Number of employees |
| Employees | 5,541 | at 2018-03-31d | Cons. | Number of employees |
| Revenue | ¥17.1bn | 2021-04-01 → 2022-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥15.0bn | 2020-04-01 → 2021-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥40.1bn | 2019-04-01 → 2020-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥9.3bn | 2018-04-01 → 2019-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥13.1bn | 2017-04-01 → 2018-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥8.7bn | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Operating income | ¥6.9bn | 2020-04-01 → 2021-03-31 | Standalone | Operating income |
| Ordinary income | ¥4.2bn | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥7.7bn | 2020-04-01 → 2021-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥32.7bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.0bn | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥6.5bn | 2017-04-01 → 2018-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥2.8bn | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Profit before tax | −¥3.2bn | 2020-04-01 → 2021-03-31 | Standalone | Income before income taxes |
| Net income | ¥5.9bn | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | ¥115m | 2020-04-01 → 2021-03-31 | Standalone | Profit loss |
| Net income | ¥27.7bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥1.6bn | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥35.1bn | 2017-04-01 → 2018-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥173.7bn | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥167.7bn | at 2021-03-31 | Standalone | Assets |
| Total assets | ¥161.3bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥117.1bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥102.8bn | at 2018-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥114.9bn | at 2022-03-31 | Standalone | Liabilities |
| Total liabilities | ¥107.2bn | at 2021-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥58.8bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥60.5bn | at 2021-03-31 | Standalone | Net assets |
| Net assets / equity | ¥66.9bn | at 2020-03-31d | Standalone | Net assets |
| Net assets / equity | ¥47.0bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥53.1bn | at 2018-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥38.3bn | at 2022-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥36.8bn | at 2021-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥103.08 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥2.02 | 2020-04-01 → 2021-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥485.53 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥28.61 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-614.83 | 2017-04-01 → 2018-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥103.05 | 2021-04-01 → 2022-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥2.02 | 2020-04-01 → 2021-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥485.42 | 2019-04-01 → 2020-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥28.6 | 2018-04-01 → 2019-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥125 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥144 | 2020-04-01 → 2021-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥130 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥130 | 2018-04-01 → 2019-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥130 | 2017-04-01 → 2018-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,032.83 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,058.77 | at 2021-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,171.23 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥822.27 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥925.79 | at 2018-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 33.8% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.0% | at 2021-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 41.4% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.0% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 51.4% | at 2018-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 9.9% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 0.2% | 2020-04-01 → 2021-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 48.7% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 3.3% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 57,446,657 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 57,416,407 | at 2021-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 57,387,861 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 57,361,385 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 57,334,183 | at 2018-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 330 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 304 | at 2021-03-31 | Standalone | Number of employees |
| Employees | 322 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 340 | at 2019-03-31d | Standalone | Number of employees |
| Employees | 298 | at 2018-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 72
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2021-04-01 → 2022-03-31 | ¥5.1bn |
| Reconciling Itemsreconciling | depreciation | 2021-04-01 → 2022-03-31 | ¥1.2bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2022-03-31 | −¥10.2bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2022-03-31 | −¥10.2bn |
| Reconciling Itemsreconciling | segment assets | at 2022-03-31 | ¥25.8bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2022-03-31 | −¥1.7bn |
| Clinical Lab Testing Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥23.1bn |
| Clinical Lab Testing Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥8.5bn |
| Clinical Lab Testing Businessreportable segment | employees | at 2022-03-31 | 2178 pure |
| Clinical Lab Testing Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥180.2bn |
| Clinical Lab Testing Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥179.9bn |
| Clinical Lab Testing Businessreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥306m |
| Clinical Lab Testing Businessreportable segment | segment assets | at 2022-03-31 | ¥142.1bn |
| Clinical Lab Testing Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥23.6bn |
| In Vitro Diagnostics Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥10.8bn |
| In Vitro Diagnostics Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥3.3bn |
| In Vitro Diagnostics Businessreportable segment | employees | at 2022-03-31 | 1034 pure |
| In Vitro Diagnostics Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥74.2bn |
| In Vitro Diagnostics Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥64.3bn |
| In Vitro Diagnostics Businessreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥9.8bn |
| In Vitro Diagnostics Businessreportable segment | segment assets | at 2022-03-31 | ¥105.6bn |
| In Vitro Diagnostics Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥26.7bn |
| Sterilization And Related Servicesreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥2.7bn |
| Sterilization And Related Servicesreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥1.5bn |
| Sterilization And Related Servicesreportable segment | employees | at 2022-03-31 | 1128 pure |
| Sterilization And Related Servicesreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥28.7bn |
| Sterilization And Related Servicesreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥28.7bn |
| Sterilization And Related Servicesreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥22m |
| Sterilization And Related Servicesreportable segment | segment assets | at 2022-03-31 | ¥13.1bn |
| Sterilization And Related Servicesreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥1.8bn |
| —segment total | capex | 2021-04-01 → 2022-03-31 | ¥36.6bn |
| —segment total | depreciation | 2021-04-01 → 2022-03-31 | ¥13.3bn |
| —segment total | employees | at 2022-03-31 | 4340 pure |
| —segment total | revenue | 2021-04-01 → 2022-03-31 | ¥283.1bn |
| —segment total | revenue external | 2021-04-01 → 2022-03-31 | ¥272.9bn |
| —segment total | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥10.2bn |
| —segment total | segment assets | at 2022-03-31 | ¥260.8bn |
| —segment total | segment profit | 2021-04-01 → 2022-03-31 | ¥52.2bn |
| Reconciling Itemsreconciling | capex | 2020-04-01 → 2021-03-31 | ¥2.5bn |
| Reconciling Itemsreconciling | depreciation | 2020-04-01 → 2021-03-31 | ¥831m |
| Reconciling Itemsreconciling | revenue | 2020-04-01 → 2021-03-31 | −¥6.5bn |
| Reconciling Itemsreconciling | revenue intersegment | 2020-04-01 → 2021-03-31 | −¥6.5bn |
| Reconciling Itemsreconciling | segment assets | at 2021-03-31 | ¥29.6bn |
| Reconciling Itemsreconciling | segment profit | 2020-04-01 → 2021-03-31 | −¥2.3bn |
| Clinical Lab Testing Businessreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥17.5bn |
| Clinical Lab Testing Businessreportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥7.0bn |
| Clinical Lab Testing Businessreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥141.1bn |
| Clinical Lab Testing Businessreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥140.9bn |
| Clinical Lab Testing Businessreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥220m |
| Clinical Lab Testing Businessreportable segment | segment assets | at 2021-03-31 | ¥124.6bn |
| Clinical Lab Testing Businessreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥12.6bn |
| In Vitro Diagnostics Businessreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥5.7bn |
| In Vitro Diagnostics Businessreportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥2.9bn |
| In Vitro Diagnostics Businessreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥56.3bn |
| In Vitro Diagnostics Businessreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥50.0bn |
| In Vitro Diagnostics Businessreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥6.2bn |
| In Vitro Diagnostics Businessreportable segment | segment assets | at 2021-03-31 | ¥83.8bn |
| In Vitro Diagnostics Businessreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥12.8bn |
| Sterilization And Related Servicesreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥1.7bn |
| Sterilization And Related Servicesreportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥1.4bn |
| Sterilization And Related Servicesreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥32.1bn |
| Sterilization And Related Servicesreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥32.1bn |
| Sterilization And Related Servicesreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥20m |
| Sterilization And Related Servicesreportable segment | segment assets | at 2021-03-31 | ¥14.7bn |
| Sterilization And Related Servicesreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥2.3bn |
| —segment total | capex | 2020-04-01 → 2021-03-31 | ¥24.9bn |
| —segment total | depreciation | 2020-04-01 → 2021-03-31 | ¥11.3bn |
| —segment total | revenue | 2020-04-01 → 2021-03-31 | ¥229.5bn |
| —segment total | revenue external | 2020-04-01 → 2021-03-31 | ¥223.0bn |
| —segment total | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥6.5bn |
| —segment total | segment assets | at 2021-03-31 | ¥223.1bn |
| —segment total | segment profit | 2020-04-01 → 2021-03-31 | ¥27.7bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,735
| Item | Context | Value | Unit |
|---|---|---|---|
| Other net fin cf | Prior1YearDuration | 100000000 | JPY |
| Other net fin cf | CurrentYearDuration | 68000000 | JPY |
| Net cash provided by used in financing activities | Prior1YearDuration | -1566000000 | JPY |
| Net cash provided by used in financing activities | CurrentYearDuration | -21725000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1YearDuration | 862000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYearDuration | 886000000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YearDuration | 6610000000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYearDuration | 3528000000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 36226000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 42950000000 | JPY |
| Increase in cash and cash equivalents from newly consolidated subsidiary cce | Prior1YearDuration | 113000000 | JPY |
| Increase in cash and cash equivalents from newly consolidated subsidiary cce | CurrentYearDuration | 0 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 42950000000 | JPY |
| Cash and cash equivalents | CurrentYearInstant | 46479000000 | JPY |
| Number of consolidated subsidiaries | CurrentYearInstant | 33 | |
| Number of associates accounted for using equity method | CurrentYearInstant | 4 | |
| Notes receivable trade | CurrentYearInstant | 1651000000 | JPY |
| Accounts receivable trade | CurrentYearInstant | 55258000000 | JPY |
| Contract assets | CurrentYearInstant | 2328000000 | JPY |
| Contract liabilities | CurrentYearInstant | 523000000 | JPY |
| Salaries and bonuses sga | Prior1YearDuration | 12633000000 | JPY |
| Salaries and bonuses sga | CurrentYearDuration | 12724000000 | JPY |
| Provision for bonuses sga | Prior1YearDuration | 3217000000 | JPY |
| Provision for bonuses sga | CurrentYearDuration | 3350000000 | JPY |
| Retirement benefit expenses sga | Prior1YearDuration | 694000000 | JPY |
| Retirement benefit expenses sga | CurrentYearDuration | 749000000 | JPY |
| Depreciation sga | Prior1YearDuration | 2378000000 | JPY |
| Depreciation sga | CurrentYearDuration | 2744000000 | JPY |
| Amortization of goodwill sga | Prior1YearDuration | 403000000 | JPY |
| Amortization of goodwill sga | CurrentYearDuration | 99000000 | JPY |
| Commission fee sga | Prior1YearDuration | 8293000000 | JPY |
| Commission fee sga | CurrentYearDuration | 15456000000 | JPY |
| Research and development expenses sga | Prior1YearDuration | 5944000000 | JPY |
| Research and development expenses sga | CurrentYearDuration | 7281000000 | JPY |
| Research and development expenses sga | Prior1YearDuration | 5944000000 | JPY |
| Research and development expenses sga | CurrentYearDuration | 7281000000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember | 140898000000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember | 50030000000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember | 32087000000 | JPY |
| Revenues from external customers | Prior1YearDuration_ReportableSegmentsMember | 223016000000 | JPY |
| Revenues from external customers | Prior1YearDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YearDuration | 223016000000 | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember | 220000000 | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember | 6247000000 | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember | 20000000 | JPY |
| Transactions with other segments | Prior1YearDuration_ReportableSegmentsMember | 6488000000 | JPY |
| Transactions with other segments | Prior1YearDuration_ReconcilingItemsMember | -6488000000 | JPY |
| Transactions with other segments | Prior1YearDuration | － | JPY |
| Net sales | Prior1YearDuration_jpcrp030000-asr_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember | 141119000000 | JPY |
| Net sales | Prior1YearDuration_jpcrp030000-asr_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember | 56278000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |